What changed from existing technology?
This study tested a new type of nano-sized medicine made from a special gel and a protein, which was given through the nose to treat depression in mice. The medicine seems to work by affecting certain proteins in the nose that are linked to mood.
This study is the first to explore the use of lactoferrin-modified sodium alginate nanogels for intranasal delivery of saikosaponin A, and to investigate the role of olfactomedin-family proteins in antidepressant effects.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
nges in the hippocampus and striatum were observed by hematoxylin and eosin staining. Western blotting was used to detect the expression of OLFM-1, OLFM-
Abstract ↗OpenAlex author affiliations: Innovation Team (China)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Validation stage
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This nanogel formulation may offer a new approach for nasal delivery of saikosaponin A, potentially improving treatment options for depression, though further research is needed to confirm its efficacy in humans.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchAntidepressant Effects of Lactoferrin-Modified Sodium Alginate-Based Saikosaponin A Nanogels via Intranasal Administration: Involvement of Olfactomedin-Family ProteinsPharmaceuticals · Published 2026-09-09 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.